3 results
Primary Objective: To verify the main effect of TDCS on brain excitability and the interaction effects of BDNF genotype and APLM latency on this main effect. Secondary Objectives: Compare different prediction models for the main effect of TDCS in a…
Primary Objective: Safety Run-in Period:To evaluate the occurrence of tumor lysis syndrome (TLS) and doselimiting toxicities (DLTs) with the concurrent administration of ibrutinib and venetoclax.Randomization Phase:To evaluate whether the…
Primary ObjectiveThe primary objective of the study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzumab plus chlorambucil (G-Clb) as assessed by an Independent Review…